A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. [electronic resource]
Producer: 20151026Description: 1667-75 p. digitalISSN:- 1468-2060
- Adrenal Cortex Hormones -- therapeutic use
- Adult
- Antibodies, Antinuclear -- immunology
- Antimalarials -- therapeutic use
- Complement C3 -- immunology
- Complement C4 -- immunology
- Double-Blind Method
- Female
- Humans
- Immunologic Factors -- administration & dosage
- Lupus Erythematosus, Systemic -- drug therapy
- Male
- Recombinant Fusion Proteins -- administration & dosage
- Severity of Illness Index
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.